| Literature DB >> 26529596 |
Susanne F Awad1, Sema K Sgaier2, Gertrude Ncube3, Sinokuthemba Xaba3, Owen M Mugurungi3, Mutsa M Mhangara3, Fiona K Lau4, Yousra A Mohamoud1, Laith J Abu-Raddad5.
Abstract
BACKGROUND: The voluntary medical male circumcision (VMMC) program in Zimbabwe aims to circumcise 80% of males aged 13-29 by 2017. We assessed the impact of actual VMMC scale-up to date and evaluated the impact of potential alterations to the program to enhance program efficiency, through prioritization of subpopulations. METHODS ANDEntities:
Mesh:
Year: 2015 PMID: 26529596 PMCID: PMC4646702 DOI: 10.1371/journal.pone.0140818
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Definitions of outcome measures in the three-level conceptual framework.
| Measure | Definition |
|---|---|
| Level 1 | |
|
| Total number of VMMCs per HIV infection averted |
|
| Cost per HIV infection averted |
|
| HIV incidence rate reduction |
|
| Total number of HIV infections averted over a given time period |
|
| Total cost of the VMMC program |
| Level 2 | |
|
| Examines the incremental change in total VMMC program cost relative to the incremental change in total number of HIV infections averted |
|
| Delineates the different possible policy
domains based on the theme of maximizing program efficiency
(maximizing gain while minimizing pain, Gain/Pain index |
|
| Delineates the different possible policy domains based on the theme of maximizing the total impact of the VMMC program (number of HIV infections averted) |
| Level 3 | |
|
| Feasibility based on on-the-ground country experiences |
Voluntary medical male circumcision (VMMC) program scenarios are assessed based on epidemiological and health economics measures (Level 1), program efficiency and policy outcome measures (Level 2), and programmatic feasibility (Level 3).
* Gain/Pain index: the proportional reduction in the total number of infections averted (Gain) over the proportional reduction in the total VMMC program cost (Pain). These proportions are assessed relative to the baseline scenario of targeting males aged 15–49 years.
Epidemic impact of prioritizing different age-group bands and brackets through the voluntary medical male circumcision (VMMC) program.
| Age group | #VMMC/HIA (2010–25) | #VMMCs (2010–17) (millions) | Additional VMMCs (2018–25) (millions) | HIA (millions) (2010–25) | Cost (USD)/HIA (2010–25) | Total cost (billion) (2010–25) |
|---|---|---|---|---|---|---|
| 15–49 | 11 | 2.52 | 1.1 | 0.33 | 1,010 | 0.33 |
| 13–29 | 11 | 2.17 (86%) | 1.3 | 0.31 (96%) | 934 (92%) | 0.29 (89%) |
| 13–29 | 12 | 2.32 (92%) | 1.3 | 0.29 (88%) | 1,035 (102%) | 0.30 (90%) |
| 10–14 | 19 | 1.32 (52%) | 1.3 | 0.14 (41%) | 1,483 (147%) | 0.20 (61%) |
| 15–19 | 11 | 1.17 (46%) | 1.2 | 0.20 (63%) | 917.32 (91%) | 0.19 (57%) |
| 20–24 | 10 | 0.99 (39%) | 1.0 | 0.21 (64%) | 811 (80%) | 0.17 (51%) |
| 25–29 | 12 | 0.80 (32%) | 0.9 | 0.14 (43%) | 1,059 (105%) | 0.15 (45%) |
| 30–34 | 15 | 0.63 (25%) | 0.7 | 0.09 (28%) | 1,377 (136%) | 0.12 (38%) |
| 35–39 | 19 | 0.49 (20%) | 0.6 | 0.06 (17%) | 1,857 (184%) | 0.10 (31%) |
| 40–44 | 28 | 0.39 (15%) | 0.5 | 0.03 (10%) | 2,769 (247%) | 0.09 (26%) |
| 45–49 | 53 | 0.28 (11%) | 0.4 | 0.01 (4%) | 5,518 (546%) | 0.07 (21%) |
| 15–24 | 11 | 1.57 (62%) | 1.3 | 0.27 (83%) | 873 (86%) | 0.23 (70%) |
| 15–29 | 11 | 1.86 (74%) | 1.3 | 0.30 (91%) | 888 (88%) | 0.26 (78%) |
| 15–34 | 11 | 2.08 (83%) | 1.2 | 0.31 (96%) | 915 (91%) | 0.39 (87%) |
| 10–24 | 13 | 2.19 (87%) | 1.5 | 0.28 (86%) | 1,061 (105%) | 0.29 (88%) |
| 10–29 | 13 | 2.49 (99%) | 1.5 | 0.31 (96%) | 1,039 (103%) | 0.32 (97%) |
| 10–34 | 12 | 2.72 (108%) | 1.4 | 0.33 (102%) | 1,044 (103%) | 0.35 (105%) |
| 10–49 | 13 | 3.14 (125%) | 1.3 | 0.35 (107%) | 1,118 (111%) | 0.44 (131%) |
The number of VMMCs needed to avert one HIV infection (2010–2025) (effectiveness), the total number of VMMCs needed to reach 80% coverage by 2017, the additional number of VMMCs needed during the sustainability phase (2018–2025), the total number of HIV infections averted (2010–2025) (magnitude of impact), the cost needed to avert one HIV infection (2010–2025) (cost-effectiveness), and the total program cost (2010–2025) (program cost). Targeting the 15–49 year old male population is used as the baseline VMMC intervention scenario for comparison purposes. The numbers in parentheses indicate the fractions achieved relative to the baseline.
* 29% of all VMMCs are among males 13–14 year old and 71% are among males 15–29 year old.
VMMC: Voluntary medical male circumcision, HIA: HIV infection(s) averted.
Fig 1Projected outcomes of age-group prioritization.
A) Number of voluntary medical male circumcisions (VMMCs) needed to avert one HIV infection (effectiveness) by 2025. B) Cost per HIV infection averted by 2025 (cost-effectiveness). C) Projected incidence rate reduction throughout the years up to 2045. The results are for 80% VMMC coverage by 2017 in each of the prioritized age band.
Fig 2Program efficiency and policy domains of age-group prioritization in the voluntary medical male circumcision (VMMC) program.
A) Expansion path curve showing the incremental change in total cost of the VMMC program (program cost) relative to the incremental change in total number of HIV infections averted (magnitude of impact) for each age group- targeted scenario. The blue line shows the expansion of the program with minimal diminishing of returns, and the red line shows the expansion of the program with considerable diminishing of returns. B) Frontier policy plot delineating the different policy domains based on the theme of maximizing program efficiency (maximizing gain while minimizing cost). Circle size represents the total number of HIV infections averted (magnitude of impact). C) Frontier policy plot delineating the different policy domains based on the theme of maximizing the total impact of the VMMC program. Circle size represents the total number of VMMCs needed. In both B and C, the orange circles represent the age brackets that fit into the optimal policy domain, the red circles represent Zimbabwe’s current targeted age group (13–29 year old males), and the blue circle represents the baseline VMMC intervention scenario. * Gain/Pain index: the proportional reduction in the total number of infections averted (Gain) over the proportional reduction in the total VMMC program cost (Pain). These proportions are assessed relative to the baseline scenario of targeting males aged 15–49 years.
Fig 3Projected outcomes of geographic and sexual risk-group prioritization.
A) Number of voluntary medical male circumcisions (VMMCs) needed to avert one HIV infection (effectiveness) by 2025 through geographic prioritization. B) Number of VMMCs needed to avert one HIV infection by 2025 through risk-group prioritization. C) Expansion path curve showing the incremental change in total cost of the VMMC program relative to the incremental change in total number of HIV infections averted for each sexual risk-group targeted scenario. The blue line shows the expansion of the program with minimal diminishing of returns, and the red line shows the expansion of the program with considerable diminishing of returns.
Fig 4Range of uncertainty for the number of voluntary medical male circumcisions (VMMCs) needed to avert one HIV infection by 2025 for the different prioritized age groups.
The solid red line represents the point estimate curve. The dashed lines bracket the 95% uncertainty interval of the curves generated in the uncertainty analyses.